{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:13:27Z","timestamp":1767856407708,"version":"3.49.0"},"reference-count":48,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/653"],"award-info":[{"award-number":["CAN 2018\/653"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival. The survival time is strongly influenced by the subtype of the tumor. Dyspnea and accumulation of pleural effusion in the pleural cavity are common symptoms of MPM. The diagnostic distinction from other malignancies and reactive conditions is done using histopathology or cytopathology, always supported by immunohistochemistry, and sometimes also by analyses of soluble biomarkers in effusion supernatant. We evaluated the soluble angiogenesis related molecules as possible prognostic and diagnostic biomarkers for MPM by Luminex multiplex assay. Pleural effusion from 42 patients with malignant pleural mesothelioma (MPM), 36 patients with adenocarcinoma (AD) and 40 benign (BE) effusions were analyzed for 10 different analytes that, in previous studies, were associated with angiogenesis, consisting of Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, Syndecan-1 (SDC-1) and VEGF by a Human Premixed Multi-Analyte Luminex kit. We found that shed SDC-1 and MMP-7 levels were significantly lower, whereas Mesothelin and Galectin-1 levels were significantly higher in malignant mesothelioma effusions, compared to adenocarcinoma. Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-\u03b21, VEGF and TIMP-1 were significantly higher in malignant pleural mesothelioma effusions compared to benign samples. Moreover, there is a negative correlation between Mesothelin and shed SDC-1 and positive correlation between VEGF, Angiopoietin-1 and shed SDC-1 level in the pleural effusion from malignant cases. Shed SDC-1 and VEGF have a prognostic value in malignant mesothelioma patients. Collectively, our data suggest that MMP-7, shed SDC-1, Mesothelin and Galectin-1 can be diagnostic and VEGF and SDC-1 prognostic markers in MPM patients. Additionally, Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1 and TIMP-1 can be diagnostic for malignant cases.<\/jats:p>","DOI":"10.3390\/biom10081113","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T03:36:38Z","timestamp":1596080198000},"page":"1113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multiplex Soluble Biomarker Analysis from Pleural Effusion"],"prefix":"10.3390","volume":"10","author":[{"given":"Joman","family":"Javadi","sequence":"first","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Huddinge University Hospital, SE-14186 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Huddinge University Hospital, SE-14186 Stockholm, Sweden"},{"name":"Karolinska University Hospital, Karolinska University laboratory, Huddinge University Hospital, SE-14186 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital, Karolinska University laboratory, Huddinge University Hospital, SE-14186 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/15287394.2019.1694612","article-title":"Pleural mesothelioma and lung cancer: The role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes","volume":"82","author":"Celsi","year":"2019","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_2","unstructured":"Maat, A., Durko, A., Thuijs, D., Bogers, A., and Mahtab, E. (2019). Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma. Multimed. Man. Cardiothorac. Surg., 2019."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5858\/arpa.2018-0020-RA","article-title":"Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines","volume":"142","author":"Hjerpe","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Vimercati, L., Cavone, D., Caputi, A., Delfino, M.C., De Maria, L., Ferri, G.M., and Serio, G. (2019). Malignant mesothelioma in construction workers: The Apulia regional mesothelioma register, Southern Italy. BMC Res. Notes, 12.","DOI":"10.1186\/s13104-019-4675-4"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/117727190700200008","article-title":"Expression of cancer-associated molecules in malignant mesothelioma","volume":"2","author":"Davidson","year":"2007","journal-title":"Biomark. Insights"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Medical progress\u2014Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"Jaurand","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review","volume":"8","author":"Tessari","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/1742-6413.170726","article-title":"Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology","volume":"12","author":"Hjerpe","year":"2015","journal-title":"Cytojournal"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/ARM.2019.0051","article-title":"Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm","volume":"87","author":"Sayan","year":"2019","journal-title":"Adv. Respir Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Abd Own, S., Hoijer, J., Hillerdahl, G., Dobra, K., and Hjerpe, A. (2020). Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis. Diagn. Cytopathol.","DOI":"10.1002\/dc.24395"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","article-title":"CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: Evidence and perspectives","volume":"18","author":"Schmid","year":"2017","journal-title":"Respir Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/dc.20202","article-title":"The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion","volume":"32","author":"Dejmek","year":"2005","journal-title":"Diagn. Cytopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1073\/pnas.1117560109","article-title":"Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis","volume":"109","author":"Hirose","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s13277-012-0473-5","article-title":"Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma","volume":"33","author":"Hanagiri","year":"2012","journal-title":"Tumour Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jjco\/27.5.293","article-title":"Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: Likelihood ratios for malignant mesothelioma","volume":"27","author":"Atagi","year":"1997","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_18","first-page":"1113","article-title":"Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas","volume":"31","author":"Torronen","year":"2016","journal-title":"Histol. Histopathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: A meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.athoracsur.2017.06.042","article-title":"Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma","volume":"104","author":"Burt","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sirois, A.R., Deny, D.A., Li, Y., Fall, Y.D., and Moore, S.J. (2019). Engineered Fn3 protein has targeted therapeutic effect on mesothelin-expressing cancer cells and increases tumor cell sensitivity to chemotherapy. Biotechnol. Bioeng.","DOI":"10.1002\/bit.27204"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cellsig.2015.07.017","article-title":"Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma","volume":"27","author":"Vives","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Szatmari, T., Mundt, F., Kumar-Singh, A., Mobus, L., Otvos, R., Hjerpe, A., and Dobra, K. (2017). Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1. BMC Cell. Biol., 18.","DOI":"10.1186\/s12860-017-0150-z"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/cncr.11515","article-title":"High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis","volume":"98","author":"Barbareschi","year":"2003","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-019-05347-0","article-title":"Syndecan-1 facilitates breast cancer metastasis to the brain","volume":"178","author":"Sayyad","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wang, S., Zhang, X., Wang, G., Cao, B., Yang, H., Jin, L., Cui, M., and Mao, Y. (2019). Syndecan-1 suppresses cell growth and migration via blocking JAK1\/STAT3 and Ras\/Raf\/MEK\/ERK pathways in human colorectal carcinoma cells. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6381-y"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood-2017-07-797050","article-title":"Syndecan-1 promotes Wnt\/beta-catenin signaling in multiple myeloma by presenting Wnts and R-spondins","volume":"131","author":"Ren","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejcts.2005.10.008","article-title":"Multimodality approach in management of malignant pleural mesothelioma","volume":"29","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21873\/invivo.11360","article-title":"Early-stage Clinical Characterization of Malignant Pleural Mesothelioma","volume":"32","author":"Negi","year":"2018","journal-title":"In Vivo"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000478-200101000-00004","article-title":"Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: A study with logistic regression analysis","volume":"25","author":"Carella","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.30699\/ijp.14.2.122","article-title":"The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion","volume":"14","author":"Halimi","year":"2019","journal-title":"Iran. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ledda, C., Senia, P., and Rapisarda, V. (2018). Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. Cancers, 10.","DOI":"10.3390\/cancers10060203"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mundt, F., Nilsonne, G., Arslan, S., Csuros, K., Hillerdal, G., Yildirim, H., Metintas, M., Dobra, K., and Hjerpe, A. (2013). Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072030"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e14979","DOI":"10.1097\/MD.0000000000014979","article-title":"Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis","volume":"98","author":"Gao","year":"2019","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Szatmari, T., Mundt, F., Heidari-Hamedani, G., Zong, F., Ferolla, E., Alexeyenko, A., Hjerpe, A., and Dobra, K. (2012). Novel genes and pathways modulated by syndecan-1: Implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048091"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0169-5002(00)00230-0","article-title":"High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery","volume":"32","author":"Anttonen","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/sj.bjc.6690088","article-title":"Syndecan-1 expression has prognostic significance in head and neck carcinoma","volume":"79","author":"Anttonen","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1349-7006.2001.tb01062.x","article-title":"Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer","volume":"92","author":"Fujiya","year":"2001","journal-title":"Jpn J. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000085702","article-title":"Syndecan-1 expression\u2014A novel prognostic marker in pancreatic cancer","volume":"68","author":"Juuti","year":"2005","journal-title":"Oncology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/8\/1113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:14Z","timestamp":1760176334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/8\/1113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["biom10081113"],"URL":"https:\/\/doi.org\/10.3390\/biom10081113","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]}}}